

Ana M Molina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8151072/publications.pdf>

Version: 2024-02-01

87
papers

2,158
citations

361413

20
h-index

233421

45
g-index

87
all docs

87
docs citations

87
times ranked

3129
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 1-10.	1.9	4
2	Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. <i>Cancer</i> , 2022, 128, 966-974.	4.1	24
3	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2022, 126, 430-439.	6.4	15
4	Serial ctDNA evaluation to predict clinical progression in patients with advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 532-532.	1.6	0
5	Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of ²²⁵ Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 77-77.	1.6	1
6	Quantitative assessment of PSMA imaging before and after ¹⁷⁷ Lu-PSMA-617 treatment in a Ph I/II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 37-37.	1.6	0
7	Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- ²²⁵ Ac-J591 for chemo-naïve metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS216-TPS216.	1.6	2
8	A phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 291-291.	1.6	1
9	The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. <i>Molecular Oncology</i> , 2022, 16, 2384-2395.	4.6	5
10	Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 2957-2995.	1.6	97
11	Phase I/II study of ²²⁵ Ac-J591 plus ¹⁷⁷ Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5100-TPS5100.	1.6	1
12	Phase II randomized double blind trial of axitinib (Axi) +/- PF-04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4529-4529.	1.6	8
13	Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted ¹²⁵ I emitting radionuclide therapies in metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 279-285.	2.3	14
14	A phase I/II dose-escalation study of fractionated and multiple dose ²²⁵ Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS188-TPS188.	1.6	2
15	Phase I trial of apalutamide (Apa) with abiraterone acetate (AA) plus prednisone (P) and docetaxel (Doce) in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 140-140.	1.6	0
16	Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 630589.	2.8	26
17	Pilot study of anti-prostate-specific membrane antigen (PSMA) antibody J591 for men with metastatic castration-resistant prostate cancer (mCRPC) and unfavorable circulating tumor cell (CTC) count.. <i>Journal of Clinical Oncology</i> , 2021, 39, 120-120.	1.6	1
18	Baseline and post-treatment circulating tumor cell (CTC) counts with prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 158-158.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC). <i>Cancer</i> , 2021, 127, 2204-2212.	4.1	32
20	Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or activating mutations in gene targets who have received prior anti-androgen therapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5095-TPS5095.	1.6	0
21	Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4515-4515.	1.6	5
22	Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5055-5055.	1.6	0
23	Phase I study of ²²⁵ Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5015-5015.	1.6	24
24	A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2021, 80, 162-170.	1.9	41
25	Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. <i>Oncologist</i> , 2021, 26, e1971-e1981.	3.7	11
26	NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2020, 38, 1383-1389.	2.6	10
27	Combined Metabolomics and Genome-Wide Transcriptomics Analyses Show Multiple HIF1 α -Induced Changes in Lipid Metabolism in Early Stage Clear Cell Renal Cell Carcinoma. <i>Translational Oncology</i> , 2020, 13, 177-185.	3.7	22
28	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020, 16, 811-819.	2.9	35
29	Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177Lu-J591) for metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 848.e9-848.e16.	1.6	29
30	Common germline-somatic variant interactions in advanced urothelial cancer. <i>Nature Communications</i> , 2020, 11, 6195.	12.8	21
31	Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.	4.1	22
32	Safety and Efficacy of Nivolumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 461-468.e3.	1.9	60
33	Safety and Efficacy of Nivolumab in Patients With Advanced Clear Cell Renal Cell Carcinoma: Results From the Phase IIIb/IV CheckMate 374 Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 469-476.e4.	1.9	16
34	Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (177Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. <i>Oncologist</i> , 2020, 25, 477-e895.	3.7	26
35	Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5560-5560.	1.6	9
36	Dose-escalation results of a phase I study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 114-114.	1.6	17

#	ARTICLE	IF	CITATIONS
37	A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC).. Journal of Clinical Oncology, 2020, 38, 685-685.	1.6	9
38	Cell cycle inhibition to target the Evolution of urothelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. Journal of Clinical Oncology, 2020, 38, TPS606-TPS606.	1.6	1
39	Phase II randomized controlled trial (RCT) of medical intensive nutrition therapy (MINT) to improve chemotherapy (CT) tolerability in malnourished patients with solid tumor malignancies.. Journal of Clinical Oncology, 2020, 38, 12090-12090.	1.6	0
40	Cell cycle inhibition to target the Evolution of urothelial cancer (CLONEVO): A single-arm, open-label window-of-opportunity trial of neoadjuvant abemaciclib in platinum-ineligible muscle invasive bladder cancer patients.. Journal of Clinical Oncology, 2020, 38, TPS5096-TPS5096.	1.6	0
41	Abiraterone acetate (AA) with or without cabazitaxel (CBZ) in treatment of chemotherapy naive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 84-84.	1.6	0
42	Patient-reported outcomes (PRO) from a phase I/II dose-escalation study of fractionated dose ¹⁷⁷ Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 45-45.	1.6	1
43	Serial circulating tumor DNA (ctDNA) measurement to predict progression in patients (pts) with advanced urothelial carcinoma (aUC).. Journal of Clinical Oncology, 2020, 38, 558-558.	1.6	0
44	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nature Communications, 2019, 10, 2977.	12.8	140
45	Clinical features of neuroendocrine prostate cancer. European Journal of Cancer, 2019, 121, 7-18.	2.8	195
46	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. JCO Precision Oncology, 2019, 3, 1-12.	3.0	24
47	Phase 1/2 study of fractionated dose lutetium- ¹⁷⁷ Lu-labeled anti- ¹⁷⁷ Lu-PSMA-617 (labeled anti- ¹⁷⁷ Lu-PSMA-617) for metastatic castration-resistant prostate cancer. Cancer, 2019, 125, 2561-2569.	4.1	100
48	Validation of risk factors for recurrence of renal cell carcinoma: Results from a large single-institution series. PLoS ONE, 2019, 14, e0226285.	2.5	12
49	Safety and efficacy of nivolumab plus ipilimumab (NIVO+IPI) in patients with advanced renal cell carcinoma (aRCC) with brain metastases: Interim analysis of CheckMate 920.. Journal of Clinical Oncology, 2019, 37, 4517-4517.	1.6	28
50	Association of noninvasive, radiographic measurement of prostate-specific membrane antigen (PSMA) expression with response to PSMA-targeted radionuclide therapy (TRT).. Journal of Clinical Oncology, 2019, 37, 5013-5013.	1.6	1
51	Neutrophil-to-lymphocyte ratio as a prognostic biomarker for overall survival in men with advanced prostate cancer treated with platinum chemotherapy.. Journal of Clinical Oncology, 2019, 37, 266-266.	1.6	1
52	Value of serum neuroendocrine markers in evaluation of neuroendocrine prostate cancer: A validation study using metastatic biopsies.. Journal of Clinical Oncology, 2019, 37, 278-278.	1.6	21
53	Efficacy and safety of nivolumab in patients with non-clear cell renal cell carcinoma (RCC): Results from the phase IIIb/IV CheckMate 374 study.. Journal of Clinical Oncology, 2019, 37, 562-562.	1.6	15
54	Preoperative radiotherapy for high-risk prostate cancer (PORT-PC) trial.. Journal of Clinical Oncology, 2019, 37, TPS137-TPS137.	1.6	0

#	ARTICLE	IF	CITATIONS
55	The genomic landscape of metastatic clear cell renal cell carcinoma (ccRCC) after treatment with systemic therapy.. Journal of Clinical Oncology, 2019, 37, 675-675.	1.6	0
56	Phase I/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, TPS339-TPS339.	1.6	1
57	Serial ctDNA tracking reveals clonal evolution dynamics in advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2019, 37, 401-401.	1.6	1
58	Somatic alterations in a seven-gene DDR gene panel predicts platinum sensitivity in advanced prostate cancer patients.. Journal of Clinical Oncology, 2019, 37, 283-283.	1.6	0
59	Multi-gene hereditary cancer testing, family history and prognosis in men with prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5073-5073.	1.6	0
60	Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 4567-4567.	1.6	1
61	Title is missing!. , 2019, 14, e0226285.		0
62	Title is missing!. , 2019, 14, e0226285.		0
63	Title is missing!. , 2019, 14, e0226285.		0
64	Title is missing!. , 2019, 14, e0226285.		0
65	Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. European Journal of Cancer, 2018, 94, 87-94.	2.8	31
66	A multidisciplinary approach for the management of earlier stage renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 15-16.	1.6	6
67	Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. Clinical Cancer Research, 2018, 24, 4399-4406.	7.0	44
68	Phase I dose-escalation study of ²²⁵ Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, TPS399-TPS399.	1.6	20
69	Everolimus (E) plus bevacizumab (B) is effective first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) with papillary features (PF): Results from a phase II trial.. Journal of Clinical Oncology, 2018, 36, 627-627.	1.6	6
70	Detection of germline deleterious mutations in prostate cancer patients with use of a validated 30-gene sequencing assay.. Journal of Clinical Oncology, 2018, 36, 223-223.	1.6	0
71	Recommendations for the Management of Rare Kidney Cancers. European Urology, 2017, 72, 974-983.	1.9	36
72	Therapy for chemopretreated metastatic urothelial cancer (mUC) with the antibody-drug conjugate (ADC) sacituzumab govitecan (IMMU-132).. Journal of Clinical Oncology, 2017, 35, 327-327.	1.6	5

#	ARTICLE	IF	CITATIONS
73	Punctuated evolution of copy-number alterations to define two molecular subtypes of muscle-invasive urothelial carcinoma.. Journal of Clinical Oncology, 2017, 35, 299-299.	1.6	0
74	Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.. Journal of Clinical Oncology, 2017, 35, 5034-5034.	1.6	0
75	Phase I dose-escalation study of fractionated-dose ¹⁷⁷ Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, TPS5093-TPS5093.	1.6	0
76	Is Underutilization of Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer Contributing to Inferior Survival?. Journal of Clinical Oncology, 2016, 34, 3235-3236.	1.6	0
77	Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. Journal of Clinical Oncology, 2016, 34, 3846-3853.	1.6	69
78	Final results of 2-dose fractionation of ¹⁷⁷ Lu-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 5022-5022.	1.6	6
79	Generating a neoantigen map of advanced urothelial carcinoma by whole exome sequencing.. Journal of Clinical Oncology, 2016, 34, 354-354.	1.6	3
80	Recent advances in the management of renal cell carcinoma. F1000Research, 2016, 5, 391.	1.6	4
81	Fractionated dose radiolabeled anti-prostate specific membrane antigen (PSMA) radioimmunotherapy (¹⁷⁷ Lu-J591) for progressive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 205-205.	1.6	0
82	Prognostic impact of clinical and pathologic criteria in neuroendocrine and aggressive variant prostate cancer.. Journal of Clinical Oncology, 2016, 34, 268-268.	1.6	0
83	Metastasis-associated mutations in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, 600-600.	1.6	0
84	Clinical and genomic alternations predictive of response to sunitinib in patients with advanced renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e16109-e16109.	1.6	0
85	Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, TPS5093-TPS5093.	1.6	0
86	Metastatic Non-Clear Cell Renal Cell Carcinoma: An Evidence Based Review of Current Treatment Strategies. Frontiers in Oncology, 2015, 5, 67.	2.8	33
87	Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncology, The, 2015, 16, 1473-1482.	10.7	762